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ABSTRACT
Purpose To explore whether privacy restrictions developed to protect patients have complicated research within a 15-year surveillance
study conducted with US cancer registries.
Methods Data from enrolling 27 cancer registries over a 10-year period were examined to describe the amount of time needed to obtain
study approval. We also analyzed the proportion of patients that completed a research interview out of the total reported by the registries and
examined factors thought to influence this measure.
Results The average length of the research review process from submission to approval of the research was 7months (range, <1 to
24months), and it took 6months or more to obtain approval of the research at 41% of the cancer registries. Most registries (78%) required
additional permission steps to gain access to patients for research. After adjustment for covariates, the interview response proportion was
110% greater (ratio of response proportion = 2.1; 95% confidence interval: 1.3, 3.3) when the least restrictive versus the most restrictive
permission steps were required. An interview was more often completed for patients (or proxies) if patients were alive, within a year of being
diagnosed, or identified earlier in the study.
Conclusions Lengthy research review processes increased the time between diagnosis and provision of patient information to the
researcher. Requiring physician permission for access to patients was associated with lower subject participation. A single national
point of entry for use of cancer registry data in health research is worthy of consideration to make the research approval process efficient.
© 2016 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.
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INTRODUCTION
Health researchers may need to collect personally
identifying information coupled with clinical informa-
tion to conduct research. When doing so, researchers
encounter a diverse array of privacy restrictions at
the federal, state, and institutional levels, designed to
restrict access to personal information. These restric-
tions are essential to protect individual privacy but
may impact the ability to carry out research that bene-
fits public health.
Institutional review and privacy boards that control
disclosure of personal health information struggle with
mandated restrictions stemming from US federal and
state regulations that govern access to patient informa-
tion for health research.1,2 This web of regulation is
especially taxing for multicenter research projects that
must seek approval from numerous institution-specific
institutional review boards (IRBs). Implementation of
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the Health Insurance Portability and Accountability
Act Privacy Rule (45 CFR Part 160; Part 164, Sub-
parts A and E) in April 2003 expanded the burden on
those conducting health research.3–5 Health care pro-
viders are permitted to disclose protected health infor-
mation to state cancer registries that conduct public
health surveillance and research benefitting the general
public, without obtaining individual patient authoriza-
tion (45 CFR Part 164 and Subpart B Part 512). Under
the same law, disclosure is also permitted to those
conducting postmarketing surveillance of medications
mandated by the US Food and Drug Administration.
The Food and Drug Administration required a
15-year postapproval surveillance study to monitor
the long-term safety of an osteoporosis medication
(teriparatide, manufactured by Eli Lilly & Co.).6 The
study is a retrospective case series initiated at the time
of drug approval in 2002. Methods and interim find-
ings from this study have been described.7 In the
study, adult patients in the USA diagnosed with osteo-
sarcoma (a rare bone cancer) or other protocol-defined
tumors are identified by cancer registries and
interviewed to determine prior drug treatments. Here,
we report on the delay in study approval and potential
impact of increasingly restrictive steps to obtain access
to conduct a noninterventional, patient contact study.
METHODS
Between February 2003 and May 2013, RTI Interna-
tional (RTI) researchers enrolled 27 cancer registries
to participate in the surveillance study and offered
assistance with IRB and other applications and
approvals. The study was approved by IRBs at RTI
and 20 registries; seven registries did not require local
IRB review during initial approval. Human subjects’
protection and other required reviews varied by regis-
try. Data collection started in July 2004 and will
continue until 2019 for patients diagnosed 1 January
2003 through 31 December 2017.
We examined two indicators of research progress:
the time needed to obtain final study approval and re-
sponse proportion. The time needed to obtain final
study approval was the time from submission of a
working protocol to a cancer registry until the later
of the date of initial IRB approval or registry approval.
Response proportion was the proportion of patients
who completed an interview of the total reported to
RTI by the registries. We could not examine response
proportion for patients at those cancer registries that
collected their own permission because only limited
data were available from these registries when
permission was not obtained. We examined factors
thought to influence these indicators.
We defined ease of access to patients by (1) how the
patient information was reported to RTI and (2) the
steps required before patients were invited to partici-
pate. Research lag time was the time elapsed between
the diagnosis date and the date patient contact infor-
mation was reported to RTI. Some cancer registries
were permitted to release patient contact information
directly to RTI; other registries required permission
from the physician and/or patient before this informa-
tion could be released to RTI (Figure 1).
Each cancer registry had unique permission steps
that needed to be followed, based on the local level
of privacy restriction required, before RTI could invite
patients to participate in the study. We assigned each
registry into one of three permission categories at the
time of the data cut, 31 March 2014. For the least re-
strictive permission category, the patient’s physician
was notified that RTI would invite the patient to partic-
ipate in the study if the physician did not object. For
the moderately restrictive permission category, per-
mission must have been obtained (by the registry or
RTI) from the patient before RTI invited the patient
to participate. For the most restrictive permission cate-
gory, permission must have been obtained from the
physician, and for some registries also the patient, be-
fore RTI could invite the patient to participate (Table 1).
Analyses
A descriptive analysis summarized the time necessary
to obtain final study approval; this analysis was also
stratified by the registries’ requirement for local IRB
approval versus not requiring local IRB approval.
To evaluate the characteristics of the patient
population, we compared demographic information
for patients reported directly to RTI versus patients
where additional permissions were required before
contact information was released to RTI. Patient-level
demographic information that included vital status,
age, sex, geographic region, and year of diagnosis
was available for comparison for all patients identified
by participating cancer registries, irrespective of
whether the registries were able to obtain permission
to release contact information to RTI. Subsequent
analyses were limited to data from patients whose
contact information was released directly to RTI where
registry-level and patient-level factors could be evalu-
ated for each observation.
To evaluate if the response proportion was associ-
ated with the level of privacy restriction or other
patient demographics or registry characteristics, we
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Table 1. Permission steps and permission category for gaining access to patient contact information for the osteosarcoma surveillance study
Permission step
Who initiates
contact? Description of steps Permission category
Physician
notification only
Researcher Researcher sends a notification about the study to the patient’s physician.
If the physician does not object to the patient being contacted for the study
the researcher is allowed to contact the patient.
Least restrictive
Patient release Either researcher
or registry
If the registry initiates patient contact, a patient permission form must be
obtained by the registry before the patient’s contact information can be
released to the researcher. If the researcher initiates contact, a patient
release form must be obtained before interviewers may contact the patient.
Moderately restrictive
Physician notification
and patient release
Registry The physician is notified and allowed to object, and the cancer registry must
obtain a permission form from the patient before the researcher may contact
the patient to participate in the study.
Moderately restrictive
Physician permission Either researcher
or registry
If the registry initiates contact, permission must be obtained from the physician
before contact information can be released to researcher. If the researcher initiates
contact, permission from the physician must be obtained before interviewers may
contact the patient. No patient release is required.
Most restrictive
Physician permission
and patient release
Registry The registry must obtain permission from both the physician and the patient
before contact information for the patient is released to the researcher.
Most restrictive
Figure 1. Cancer Registry Patient Contact Information Flow Based on Type of Patient Information Release Policy. CR = cancer registry; RTI = RTI Interna-
tional. (a) Patient was not contacted because the physician did not provide permission (n = 130) or RTI was pending completion of a required waiting period
before being authorized to contact the patient (n = 8)
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compared the response proportion stratified by the per-
mission category, research lag time (≤1year, >1year),
type of cancer registry—National Cancer Institute,
Surveillance, Epidemiology and End Results Program
affiliated or not,8 and registry size (reflecting the
proportion of US osteosarcoma cases captured by the
registry: small, 0% to <2%; medium, 2% to <4%;
large, ≥4%). Patient-level demographic information
included vital status (alive or deceased at the time of
reporting to RTI), age, sex, and state of residence
when diagnosed (grouped by US census region). We
assessed potential for a secular trend in participation
by stratifying the response proportion by calendar year
the patient data were reported to RTI.
The ratio of the response proportions was calculated
across levels of each study variable, using one level as
the reference category. For each variable, we evaluated
potential confounding of the relationship between
permission category and response proportion by com-
paring the ratio of response proportions unadjusted for
that variable with the ratio adjusted for the same
variable. For adjustment, we calculated the response
proportion by permission category at each level of
the variable, weighted by the patients at the same level
in the overall population (patients reported directly to
RTI). In addition, we evaluated the relationship
between the permission category and the response
proportion by adjusting the ratio of response
proportions for all of the registry and patient-level
characteristics available to us by fitting a multivariate
log-binomial model.
We assumed those patients with missing values for
vital status were alive. Missing values for state of
residence when diagnosed were addressed by using
the state of the reporting registry.
All data were analyzed using SAS v9.3 (SAS
Institute Inc., Cary, NC, USA) and Episheet.9
RESULTS
Registry approval
As of 31 March 2014, of the 27 cancer registries, the
average time needed to obtain final study approval
was 7months (range, <1 to 24months); 41% of the
registries took 6months or more to obtain final study
approval (<3months, 33%; 3 to <6months, 26%; 6
to <12months, 22%; and ≥12months, 19%). Of the
20 registries requiring local IRB review, the average
time needed to obtain final study approval was
7months (range, <1 to 24months); half of these regis-
tries took 6months or more to obtain final study ap-
proval. At the seven registries not requiring local
IRB review, the average time needed to obtain final
study approval was 4months (range, <1 to 18months);
only one registry took more than 6months to obtain
final study approval.
Cancer registry and patient characteristics
Overall, 3,692 eligible patients diagnosed from January
2003 through December 2012 were identified from 27
cancer registries. Approximately 22% (n=6) of these
registries had the least restrictive permissions, 56%
(n=15) had moderately restrictive permissions, and
22% (n=6) had the most restrictive permissions. Most
registries (n=19; 70%) were not affiliated with the Na-
tional Cancer Institute.
Patient demographic characteristics were compared
between registries that released patient contact infor-
mation directly to RTI (n=2,083) and registries that
released contact information only after obtaining other
permissions (n=1,609). The populations were similar
in most respects, but patients from registries that re-
leased patient contact information directly to RTI were
more frequently diagnosed in the first 4years of the
study (38% vs 32%) and more often alive at the time
of reporting to RTI (63% vs 54%) (Table 2).
Response proportion
The response proportion and ratio of response propor-
tions among patients reported to RTI directly varied by
permission category, patient demographics, and cancer
registry characteristics (Table 3). The response propor-
tion among registries in the least restrictive permission
category was 60% greater (ratio of response propor-
tion=1.6; 95% confidence interval [CI]: 1.3, 2.0) than
for registries in the most restrictive permission cate-
gory. Research lag time showed a similar pattern.
The response proportion was 30% greater (ratio of re-
sponse proportion=1.3; 95% CI: 1.2, 1.5) if the time
from diagnosis to reporting of patient information to
RTI was 1year or less versus more than 1year. Re-
sponse proportion was associated with patient vital
status at the time of reporting to RTI and was 90%
greater (ratio of response proportion=1.9; 95% CI:
1.6, 2.2) when a patient was reported alive, even if a
proxy was located and interviewed, than when the pa-
tient was reported as deceased and had a proxy re-
sponse. Patients aged 40–49 or 60–69years had a
response proportion 30% greater (ratio of response
proportion=1.3; 95% CI: 1.1, 1.5) than that for pa-
tients aged 70years or older. Patients reported to RTI
in earlier calendar years had a higher response propor-
tion (2004–2011) than patients reported to RTI after
2011, regardless of the patient’s year of diagnosis.
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Response proportion did not vary appreciably by sex
of the patient.
A stratified analysis revealed that the year the pa-
tient was reported to RTI was a potential confounder
of the association between permission category and re-
sponse proportion. The association between response
proportion and permission category was attenuated
when controlling for the confounder. We attempted
to assess potential confounding for all covariates using
a stratified analysis; however, small-cell sizes in some
covariate strata limited our ability to assess potential
confounding using this approach.
Using a multivariate log-binomial model, we ad-
justed for the patient and registry characteristics (vital
status, age, sex, geographic region, the year the patient
was reported to RTI, research lag time, and the type
and size of the cancer registry). After adjustment, the
response proportion among registries in the least
restrictive permission category was 110% greater
(ratio of response proportion=2.1; 95% CI: 1.3, 3.3)
than for registries in the most restrictive permission
category. Similarly after adjustment, the response
proportion among registries in the moderately restric-
tive permission category was 60% greater (ratio of
response proportion=1.6; 95% CI: 1.0, 2.7) than for
registries in the most restrictive permission category.
DISCUSSION
Even with extensive collaboration with cancer registry
professionals a substantial amount of time may be
required to obtain research approval at many registries,
especially when local IRB review is required, increas-
ing the cost and burden of the research. Approval
processes are heterogeneous across registries, owing
to different state-level and institutional research
approval requirements and different interpretations of
privacy restrictions. Local requirements were frequently
conflicting and precluded using a single set of study
materials and patient contact methods, increasing the
time needed to obtain final study approval. Delays
and the effect on subject selection and participation
have been shown elsewhere to possibly limit the valid-
ity of research findings.2,5,10–14
Our research indicates that less restrictive permission
steps to gain access to patients and shorter research lag
times are associated with greater response. Patients
identified during the earlier years of the study period
had higher response proportions, which confounded
the relation between permission category and response
proportion. The confounding may be due to unmea-
sured secular trends (e.g., increasing public concern
over privacy or unwillingness to participate in research)
Table 2. Characteristics of All patients identified, patients whose contact information was reported directly to RTI, and patients whose information was re-
leased after obtaining permission
All patients identified (n = 3,692)
Patient information reported
directly to RTI (n = 2,083)
Patient information released after
permission obtained (n = 1,609)
Percentage
difference*Characteristic n % 95% CI n % 95% CI n % 95% CI
Sex
Male 1,885 51 49, 53 1,082 52 50, 54 803 50 47, 52 2
Female 1,807 49 47, 51 1,001 48 46, 50 806 50 48, 52 -2
Age (years)
Mean (SD) 63.3 (13.6) 63.8 (13.8) 62.6 (13.4)
70 or older 1,249 34 32, 35 746 36 34, 38 503 31 29, 34 5
60–69 831 23 21, 24 462 22 20, 24 369 23 21, 25 1
50–59 912 25 23, 26 495 24 22, 26 417 26 24, 28 2
40–49 700 19 18, 20 380 18 17, 20 320 20 18, 22 2
Vital status†
Deceased 1,508 41 39, 42 763 37 35, 39 745 46 44, 49 10
Alive 2,184 59 58, 61 1,320 63 61, 65 864 54 51, 56 10
Geographic region‡
Midwest 741 20 19, 21 266 13 11, 14 475 30 27, 32 17
South 1,329 36 34, 38 927 45 42, 47 402 25 23, 27 20
West 777 21 18, 22 613 29 28, 31 164 10 9, 12 19
Northeast 845 23 22, 24 277 13 12, 15 568 35 33, 38 22
Year diagnosed
2010–2012 1,146 31 30, 33 627 30 28, 32 519 32 30, 35 -2
2007–2009 1,243 34 32, 35 665 32 30, 34 578 36 34, 38 -4
2003–2006 1,303 35 34, 37 791 38 36, 40 512 32 30, 34 6
CI = confidence interval; RTI = RTI International; SD = standard deviation; US =United States.
*Reported directly to RTI—released after permission obtained.
†Patients with a missing value for vital status were assumed to be alive.
‡Geographic region assigned based on state of residence at time of diagnosis, grouped by US Census.
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or to the manner in which registries were recruited; reg-
istries with more restrictive permissions were recruited
to the study much later in the study period, which cor-
relates with the year patients were reported to RTI.
This analysis was limited; it could not use the entire
patient population identified by all participating cancer
registries due to data release policies. However, based
on similarity of patient-level characteristics, patient
data released directly to RTI did not appear to differ
from data obtained otherwise in ways that might affect
the association observed between permission category
and response proportion. It is possible that patients
with more advanced disease were less likely to partic-
ipate in the study. Although cancer registries collect
stage of disease at diagnosis, the stage data were not
available to the researchers.
Table 3. Response proportion among patients reported directly to RTI, by patient and cancer registry characteristic (n = 2,083)*
Characteristic Total in group Number interviewed (%) Ratio of response proportions† 95% CI
Patient characteristic
Vital status
Deceased 763 176 (23.1) 1.0 Ref
Alive 1,320 576 (43.6) 1.9 1.6, 2.2
Age (years)
70 or older 746 235 (31.5) 1.0 Ref
60–69 462 183 (39.6) 1.3 1.1, 1.5
50–59 495 180 (36.4) 1.2 1.0, 1.4
40–49 380 154 (40.5) 1.3 1.1, 1.5
Sex
Male 1,082 404 (37.3) 1.0 Ref
Female 1,001 348 (34.8) 0.9 0.8, 1.0
Geographic region
Midwest 266 69 (25.9) 1.0 Ref
South 927 319 (34.4) 1.3 1.1, 1.7
West 613 245 (40.0) 1.5 1.2, 1.9
Northeast 277 119 (43.0) 1.7 1.3, 2.1
Year reported to RTI
≥2012 559 151 (27.0) 1.0 Ref
2008–2011 941 361 (38.4) 1.4 1.2, 1.7
2004–2007 583 240 (41.2) 1.5 1.3, 1.8
Cancer registry characteristic
Permission category
Most restrictive 297 73 (24.6) 1.0 Ref
Moderately restrictive 675 248 (36.7) 1.5 1.2, 1.9
Least restrictive 1,111 431 (38.8) 1.6 1.3, 2.0
Research lag time‡
>1 year 1,363 446 (32.7) 1.0 Ref
≤1 year 720 306 (42.5) 1.3 1.2, 1.5
Type of cancer registry
Non-NCI 1,532 529 (34.5) 1.0 Ref
NCI 551 223 (40.5) 1.2 1.0, 1.3
Size of the cancer registry§
Small 106 36 (34.0) 1.0 Ref
Medium 525 203 (38.7) 1.1 0.9, 1.5
Large 1,452 513 (35.3) 1.0 0.8, 1.4
Cancer registry characteristic Adjusted Ratio of Response Proportions†
Permission category
Most restrictive 297 73 (24.6) 1.0 Ref
Moderately restrictive 675 248 (36.7) 1.6 1.0, 2.7
Least restrictive 1,111 431 (38.8) 2.1 1.3, 3.3
CI = confidence interval; NCI = National Cancer Institute; RTI = RTI International; US =United States.
*Nine patients reported with contact information from participating registries were missing values for vital status. The modal value of “alive” was used for
these patients. The ratio of response proportions could not be prepared for patients whose information is released to RTI only after permission is obtained
by the cancer registry because only limited data were provided and it was not possible to determine case-specific information for those patients not
interviewed (i.e., vital status, age, and research lag time).
†Values greater than 1 indicate that a patient in the strata has a greater likelihood of being interviewed than a patient in the reference strata.
‡The time between the date of diagnosis and the date reported to the researcher.
§Size of the registry is based on the estimated coverage of incident cases of osteosarcoma in the USA from 1 January 2007, to 31 December 2012, using NCI rate
of osteosarcoma, 2.5 cases per million population per year18 applied to the annual estimates of the resident population by age and sex from 2007–2012.19 Small
registries cover less than 2% of incident cases; medium registries cover 2% to less than 4% of incident cases; large registries cover at least 4% of incident cases.
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This analysis did not account for privacy restrictions
that may have changed during the study period. How-
ever, only one state cancer registry included in the
response proportion analysis changed its policy during
the study period in a manner that changed how patients
could be contacted for this study. That change was due,
in part, to the poor patient response observed when
physician permission was required before patients
could be contacted for this study. In 2010, the registry
modified its privacy restrictions, which allowed RTI
to contact patients directly without physician permis-
sion. Prior to this change, the registry was classified
in the most restrictive permission category and had
one of the lowest patient response rates in the study.
However, in this analysis, it was classified according
to the privacy restriction after the changes went into
effect (i.e., in the least restrictive permission category),
which may have attenuated a stronger association
between permission category and response proportion.
Limited experience of cancer registries and their
IRBs with postapproval drug safety studies and possi-
ble reluctance by state health departments to engage in
research sponsored by pharmaceutical companies may
be barriers to prompt local approval of research. It is
also possible that the frequency of IRB review meet-
ings influenced the length of time to approval; how-
ever, we did not characterize this aspect of the delay
in obtaining approval. Registries often lack resources
or infrastructure to accept external funding to support
research activities, including “shepherding” research
protocols through internal review processes.
These findings and others15 suggest that streamlining
protocol review and permission steps to gain access to
patients would reduce the burden to researchers
conducting studies with cancer registries. One sugges-
tion would be consideration of a single, centralized
process for approval and access to cancer registry data.
For example, the National Death Index was created
over 35years ago to improve access to state-level
mortality records by simplifying data access for
researchers into a single approval process.16 While
some privacy and human subject’s protection issues
are different for cancer registry data,17 a similar model
might allow greater access to cancer registry data for
research of benefit to the public.
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